PD-L1 and HLA class i antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma

Clinical Cancer Research

Volumn 22, Issue 2, 2016, Pages 470-478

  Sabbatino, Francesco ^a   Villani, Vincenzo ^a   Yearley, Jennifer H ^b   Deshpande, Vikram ^a   Cai, Lei ^a   Konstantinidis, Ioannis T ^a   Moon, Christina ^b   Nota, Sjoerd ^a   Wang, Yangyang ^a   Al Sukaini, Ahmad ^a   Zhu, Andrew X ^c   Goyal, Lipika ^c   Ting, David T ^c   Bardeesy, Nabeel ^c   Hong, Theodore S ^a   Castillo, Carlos Fernandez Del ^a   Tanabe, Kenneth K ^a   Lillemoe, Keith D ^a   Ferrone, Soldano ^a   Ferrone, Cristina R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BILE DUCT CARCINOMA; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL PREDICTION; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; BILE DUCT TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; INTRAHEPATIC BILE DUCT; MIDDLE AGED; PROCEDURES; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CD8-POSITIVE T-LYMPHOCYTES; CHOLANGIOCARCINOMA; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED;

EID: 84959017229     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0715     Document Type: Article

References (38)

1. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-25.
2. Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008;42:178-90.
3. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84-96.
4. Chouaib S. At the crossroads of cancer. Bull Cancer 2013;100:569-74.
5. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial. J Clin Oncol 2013;31:4199-206.
6. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
7. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
8. Brahmer JR, Tykodi SS, Chow LQ,HwuWJ, Topalian SL,HwuP, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
10. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616-22.
11. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24:75-83.
12. Hodi FS, O'Day SJ,McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients withmetastatic melanoma. N Engl J Med 2010;363:711-23.
13. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.
14. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
15. Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol 2013; 31:4252-9.
16. Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008;14:1413-7.
17. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 2013;12: 130-46.
18. Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and NK Cell-Activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res 2005;93: 189-234.
19. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 1979;27:51-177.
20. CampoliM, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008;27:5869-85.
21. Sabbatino F, Schwab JH, Ferrone S, Ferrone CR. Evolution of studies ofHLA class I antigen processing machinery (APM) components in malignant cells. Clin Transpl 2013:453-63.
22. Esteban F, Ruiz-Cabello F, Concha A, Perez-Ayala M, Sanchez-Rozas JA, Garrido F. HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clin Exp Metastasis 1990;8: 319-28.
23. Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, et al. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia 2014; 16:31-42.
24. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, et al. In situ expression of transforming growth factor beta is associatedwith melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 1997;7:313-21.
25. Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract 1998;194:679-84.
26. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137:2299-306.
27. Sernee MF, Ploegh HL, Schust DJ. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two commonMHCclass I reagents. Mol Immunol 1998;35:177-88.
28. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003;171: 1918-26.
29. Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, Ferrone S. Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods 1993;161: 239-56.
30. Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 2003;9:4043-51.
31. Kasic T, Colombo P, Soldani C, Wang CM, Miranda E, Roncalli M, et al. Modulation of human T-cell functions by reactive nitrogen species. Eur J Immunol 2011;41:1843-9.
32. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8? T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360-5.
33. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757-66.
34. Muenst S, Schaerli AR, Gao F,Daster S, Trella E, Droeser RA, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014;146:15-24.
35. Chou FF, Sheen-Chen SM, Chen CL, Chen YS, Chen MC. Prognostic factors of resectable intrahepatic cholangiocarcinoma. J Surg Oncol 1995;59: 40-4.
36. Ye Y, Zhou L, Xie X, Jiang G, Xie H, Zheng S. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol 2009;100:500-4.
37. Suleiman Y, Coppola D, Zibadi S, Dalia S, Juan TH, Lee JK, et al. Prognostic value of tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in cholangiocarcinoma. Gastrointestinal Cancers Symposium. J Clin Oncol 2015;33:2015(suppl 3; abstr 294).
38. Umemoto Y, Okano S, Matsumoto Y, Nakagawara H,Matono R, Yoshiya S, et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol 2015;50:65-75.